Diane's Feed
Aug 27, 2013

U.S. asks for March trial in airline merger challenge

WASHINGTON (Reuters) – The U.S. Justice Department asked a federal court on Tuesday to set a March 3 trial date to hear arguments over whether it should stop a planned merger between US Airways (LCC.N: Quote, Profile, Research, Stock Buzz) and American Airlines (AAMRQ.PK: Quote, Profile, Research, Stock Buzz).

The companies had requested a 10-day trial that would begin on November 12.

The Justice Department filed a lawsuit on August 13, asking a federal court to order the companies to abandon plans for a deal to create the world’s largest carrier.

Aug 3, 2013

Obama administration overturns ban on some iPad, iPhones

WASHINGTON (Reuters) – The Obama administration has overturned a U.S. trade panel’s ban on the sale of some older iPhones and iPads, reversing a ruling that had favored Samsung Electronics Co Ltd over Apple Inc in their long-running patent battles.

The U.S. International Trade Commission in June banned the import or sale of the iPhone 4, iPhone 3GS, iPad 3G and iPad 2 3G distributed by AT&T Inc, saying the devices infringed a patent owned by the South Korean electronics giant.

Jul 29, 2013

Experts predict long antitrust road for Omnicom, Publicis

WASHINGTON/BRUSSELS (Reuters) – Publicis (PUBP.PA: Quote, Profile, Research, Stock Buzz) and Omnicom (OMC.N: Quote, Profile, Research, Stock Buzz) will most likely have to shed some assets in order for their mega deal to win approval from regulators in the United States, Europe and 40 other countries where they operate.

The deal would combine the world No. 2 agency, Omnicom, with the No. 3, Publicis, to create the world’s largest agency. The companies have expressed confidence that the transaction will move forward.

Jul 26, 2013

US court permits generic version of Teva MS drug a year sooner

WASHINGTON/NEW YORK, July 26 (Reuters) – Teva Pharmaceutical
Industries’ $4 billion-a-year multiple sclerosis drug Copaxone
will lose its patent protection in 2014 rather than 2015 because
of a ruling from a U.S. appeals court on Friday, making it
potentially prey to cheaper generics next May.

The U.S. Court of Appeals for the Federal Circuit issued its
decision in a patent fight that pits Teva against two
teams developing cheaper generic forms of Copaxone: one with
Novartis AG and Momenta Pharmaceuticals Inc
and another between Mylan Inc and Natco Pharma Ltd
.

Jul 26, 2013

US court permits generic version of Teva MS drug a year sooner

WASHINGTON/NEW YORK, July 26 (Reuters) – Teva Pharmaceutical
Industries’ $4 billion-a-year multiple sclerosis drug Copaxone
will lose its patent protection in 2014 rather than 2015 because
of a ruling from a U.S. appeals court on Friday, making it
potentially prey to cheaper generics next May.

The U.S. Court of Appeals for the Federal Circuit issued its
decision in a patent fight that pits Teva against two
teams developing cheaper generic forms of Copaxone: one with
Novartis AG and Momenta Pharmaceuticals Inc
and another between Mylan Inc and Natco Pharma Ltd
.

Jul 23, 2013

Supreme Court win boosts fight against drug settlements: FTC

WASHINGTON (Reuters) – A recent U.S. Supreme Court ruling giving regulators the right to sue drugmakers for agreements that delay cheaper generic versions of their products should deter some of the most egregious deals and allow the agency to better fight others, Federal Trade Commission Chairwoman Edith Ramirez told lawmakers on Tuesday.

At issue are deals – often called “pay for delay” – where brand-name drugmakers settle patent infringement lawsuits by paying generic companies to postpone marketing their cheaper versions of the products.

Jul 23, 2013

U.S. Supreme Court win boosts fight against drug settlements -FTC

WASHINGTON, July 23 (Reuters) – A recent U.S. Supreme Court
ruling giving regulators the right to sue drugmakers for
agreements that delay cheaper generic versions of their products
should deter some of the most egregious deals and allow the
agency to better fight others, Federal Trade Commission
Chairwoman Edith Ramirez told lawmakers on Tuesday.

At issue are deals – often called “pay for delay” – where
brand-name drugmakers settle patent infringement lawsuits by
paying generic companies to postpone marketing their cheaper
versions of the products.

Jul 19, 2013

Top U.S. funeral chain deal expected to get antitrust nod

WASHINGTON (Reuters) – Service Corp International (SCI.N: Quote, Profile, Research, Stock Buzz), the biggest U.S. funeral services company which has bought up rivals for two decades, is likely to get approval from antitrust officials for its bid to acquire the No. 2 chain, Stewart Enterprises Inc, antitrust experts told Reuters.

Houston-based Service Corp, with 13 percent of the U.S. market by revenue, said on May 29 it would buy century-old Stewart Enterprises (STEI.O: Quote, Profile, Research, Stock Buzz) for $1.13 billion.

Jul 9, 2013

U.S. debt collector hit with record penalty for abusive calls

WASHINGTON (Reuters) – Expert Global Solutions, the world’s largest debt collection agency, has agreed to pay a $3.2 million civil penalty and stop harassing and abusing debtors by engaging in practices such as calling them multiple times a day, the U.S. Federal Trade Commission said on Tuesday.

The financial penalty levied on the company is the biggest ever obtained by the FTC against a third-party debt collector, the commission said.

Jul 3, 2013

Exclusive: States join U.S. probe of Cargill/ConAgra flour deal

WASHINGTON (Reuters) – A group of wheat-growing states has joined the U.S. Justice Department in investigating a proposed joint venture by Cargill, CHS and ConAgra, which would make the largest U.S. flour miller even larger, two sources told Reuters.

About a dozen states, led by Oklahoma’s attorney general, will join the department’s antitrust division in a review of the plan by ConAgra Foods Inc (CAG.N: Quote, Profile, Research, Stock Buzz) to join Horizon Milling, a joint venture of Cargill Inc. CARG.UL and CHS Inc (CHSCP.O: Quote, Profile, Research, Stock Buzz).